Last updated: 2026-10-14 15:57:00. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Kyverna Therapeutics, Inc. (KYTX) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $5.72, with a market capitalisation of $384.05M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $5.63 to $13.67. This page covers its latest market performance, valuation, price trends and company information.
$384.05M | |
$5.76 | |
$35.06 | |
$1.78 | |
$5.77 | |
429.80K | |
854.60K | |
-- | |
$13.67 | |
$5.63 | |
-- | |
-- |
Kyverna Therapeutics, Inc. (KYTX) is currently trading at $5.72 as of 2026-10-14 15:55:00, down 0.87% ($0.05) from the previous close of $5.77
During today's regular trading session, KYTX has traded between $1.78 and $35.06, with a trading volume of 429.80K shares. The current price is near the lower end of today's range.
Over the past seven days, Kyverna Therapeutics, Inc. (KYTX) moved from $6.32 to $5.72, representing a decline of 9.49% ($0.60).
The stock traded between $5.63 and $6.58 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 865.94 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 1.2%
KYTX is currently trading at $5.72, placing it 1.2% of the way from its 52-week low of $5.63 to its 52-week high of $13.67. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 149 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kyverna Therapeutics, Inc. (KYTX) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.